Delving into the Latest Updates on Bifidobacterium(Nitto Pharmaceutical Industries Ltd.) with Synapse

Overview

Basic Info

Drug Type

Probiotics

Synonyms

Bifisgen, ビフィスゲン

Target-

Action

modulators

Mechanism

Bacteria replacements, Microbiome modulators

Therapeutic Areas

Other Diseases

Active Indication

Dysbacteriosis

Inactive Indication-

Originator Organization

Nitto Pharmaceutical Industries Ltd.

Active Organization

Nitto Pharmaceutical Industries Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

Japan (01 May 1969),

Dysbacteriosis

Regulation-

Login to view timeline

Type 2 diabetes (T2D) is known as adult-onset diabetes, but recently, T2D has increased in the number of younger people, becoming a major clinical burden in human society. The objective of this study was to determine the effects of Bifidobacterium and Lactiplantibacillus strains derived from the feces of 20 healthy humans on T2D development and to understand the mechanism underlying any positive effects of probiotics. We found that Bifidobacterium longum NBM7-1 (Chong Kun Dang strain 1; CKD1) and Lactiplantibacillus rhamnosus NBM17-4 (Chong Kun Dang strain 2; CKD2) isolated from the feces of healthy Korean adults (n = 20) have anti-diabetic effects based on the insulin sensitivity. During the oral gavage for 8 weeks, T2D mice were supplemented with anti-diabetic drugs (1.0-10 mg/kg body weight) to four positive and negative control groups or four probiotics (200 uL; 1 × 10⁹ CFU/mL) to groups separately or combined to the four treatment groups (n = 6 per group). While acknowledging the relatively small sample size, this study provides valuable insights into the potential benefits of B. longum NBM7-1 and L. rhamnosus NBM17-4 in mitigating T2D development. The animal gene expression was assessed using a qRT-PCR, and metabolic parameters were assessed using an ELISA assay. We demonstrated that B. longum NBM7-1 in the CKD1 group and L. rhamnosus NBM17-4 in the CKD2 group alleviate T2D development through the upregulation of IL-22, which enhances insulin sensitivity and pancreatic functions while reducing liver steatosis. These findings suggest that B. longum NBM7-1 and L. rhamnosus NBM17-4 could be the candidate probiotics for the therapeutic treatments of T2D patients as well as the prevention of type 2 diabetes.

01 Mar 2025·Ecotoxicology and Environmental Safety

Activation of Sirt1 by acetate alleviates silicofibrosis: Contribution of the gut microbiota

Article

Author: Qi, Xuejie ; Zhang, Weiliang ; Jia, Qiang ; Han, Mingming ; Peng, Cheng ; Li, Xixi ; Wu, Heng ; Sai, Linlin ; Shao, Hua ; Su, Chongyi ; Yin, Wenhui ; Wang, Yanhui

Silicosis is a prevalent occupational disease marked by progressive pulmonary fibrosis. Despite its significant health burden, the pathogenesis of silicosis remains unclear, and no specific therapeutic drugs are available. In this study, we developed a novel intervention strategy targeting gut microbiota and investigated its underlying mechanisms. Using 16S rRNA gene sequencing, we observed significant gut microbiota dysbiosis in silicosis rats at different times (1-8 weeks), notably characterized by altered relative abundance of Ruminococcus and Lactobacillus. Fecal microbiota transplantation altered the gut microbiota structure of silicosis rats, alleviated silica-induced lung histopathological injury, with LEfSe analysis identifying Bifidobacterium as a potential biomarker. Treatment with Bifidobacterium reduced the level of pro-inflammatory cytokines (IL-1β, IL-6 and TNF-α) and fibrosis markers (collagen III, α-SMA and vimentin) in the lungs of silicosis rats, accompanied with increased serum acetic acid levels. Acetate, a major metabolite of Bifidobacterium, demonstrated similar protective effects against silicosis in this study, suggesting its role as a key mediator of Bifidobacterium action in the lungs. Both Bifidobacterium and acetate significantly upregulated Sirt1 in intestinal and lung tissues, while Sirt1 inhibition diminished their benefits to silicosis. As a widely studied histone deacetylase, Sirt1 was proven to be markedly reduced in the lungs of silicosis rats in this study. EX-527, a potent Sirt1 inhibitor, could worsen silicosis damage by upregulating the level of TGF-β1 and the degree of Smad2/3 acetylation. Our study highlights the efficacy of postbiotics, such as Bifidobacterium and acetate, and identifies Sirt1 as a promising target for silicosis treatment.

01 Feb 2025·Journal of International Medical Research

Gut microbial profiles of patients with optic neuritis or myasthenia gravis

Article

Author: Lin, Chen ; Yu, Jie ; Jiang, Hanqiu ; Wu, Tao ; Cui, Shilei ; Peng, Jingting ; Wang, Jiawei ; Kong, Xiuyun

Objective To characterize the gut microbial composition of patients with optic neuritis (ON) or myasthenia gravis (MG). Methods Stool samples were collected from 45 patients with ON, 13 patients with MG, and 20 healthy controls. Microbial genomic DNA was extracted, and the V3–V4 regions of bacterial 16S rRNA genes were amplified and sequenced. Bioinformatic analyses was performed to compare the alpha-diversity, beta-diversity, taxonomic assignments, and bacterial richness of the groups. Differences in the abundances of microbial taxa were identified using linear discriminant analysis effect size (LEfSe) and analysis of variance. Results Beta-diversity analysis showed distinct clustering of patient samples from the healthy controls. At the phylum and genus levels, Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria predominated, but their proportions varied between groups. LEfSe analysis identified microbial taxa that were associated with each group. The patients showed lower abundances of certain intestinal probiotics, including Bifidobacterium, Bacteroides, and Roseburia, than the controls. No significant differences were found between the disease subgroups. The Carnobacteriaceae family was significantly less abundant in the ON than in the MG group. Conclusion We have identified significant alterations in the gut microbiota of patients with ON or MG, and importantly, a notable reduction in intestinal probiotics.

100 Deals associated with Bifidobacterium(Nitto Pharmaceutical Industries Ltd.)

Login to view more data